CytoDyn Securities Litigation Settlement
Checked October 14, 2026 against the official notice · Edited by Ferhat Abdullahoglu
This settlement closed on September 21, 2026
If you filed, payments follow the court's final approval (hearing November 2, 2026).
CytoDyn and former executives agreed to settle a securities class action over statements about its drug leronlimab, providing 49 million CytoDyn shares and $500,000 in cash for investors who bought CytoDyn stock between March 27, 2020 and March 30, 2022. The claim deadline was September 21, 2026; eligible claimants share the settlement pro rata, so individual amounts depend on losses and the number of claims.
Who qualifies
“All persons and entities that purchased or otherwise acquired the common stock of CytoDyn Inc.”From the court-approved notice
How to file
The claim deadline has passed. If you filed, payments follow the court's final approval.
Key dates
When settlements pay, and what can delay it.
Is this settlement legit?
Yes. It's a court-approved class action settlement, run by Strategic Claims Services. The official site is strategicclaims.net. You never pay to file a claim. How to check a settlement notice.
Related settlements
ClaimWell summarizes the official notice so it's easier to read. It isn't legal advice; the official settlement site is the authority on who qualifies and what each claim pays.